Introduction
Chlamydophila pneumoniae is an obligate intracellular bacterium that has a unique developmental cycle involving infection of the elementary body (EB; an infectious form with metabolically inactive to cells) (early stage) and subsequent maturation of the reticulate body (RB; an intracellular metabolically active but non-infectious form) to form the EB (mid to late stages) [1] . This bacterial species is a well-known cause of common human respiratory infection [2, 3] , with several studies also reporting that chronic chlamydial infection (persistent infection) can be an important clinical manifestation of persistent respiratory diseases such as asthma and atherosclerosis [4] [5] [6] .
The presence of C. pneumoniae in persistent infection is characterized by an absence of culturability [7] , in addition to altered bacterial RNA and protein levels [8] [9] [10] [11] , morphologically altered chlamydial bodies [8] and increased resistance to antimicrobials, such as azithromycin or clarithromycin, frequently used for the treatment of C. pneumoniae infection [12] . The mechanisms leading to persistent C. pneumoniae infection remain unclear; however, infection in reported cases occurred during an uncompleted developmental cycle with a lack of maturation of the EB, and an absence of bacterial metabolic activity caused a decrease in sensitivity to the antibiotics used. Consequently, many researchers have studied how intracellular bacterial persistence occurs using well-characterized epithelial HEp-2 cells and investigated which drug is most effective at eliminating bacteria that have developed to a persistent phase. Generally, persistent infection is induced by treatment with interferon (IFN) , as regulated by a broad range of bacterial genes encoding proteins associated with inclusion membranes [13] , type III machinery [14] , metabolism [15] and immunopathology [15] [16] [17] . However, an effective drug against persistent chlamydial 5 infection has yet to be discovered, and current therapy relies on potentially ineffective experimental drug treatments against chlamydial latent infection or reinfection, which are always characterized by refractory disorder.
Steroid treatment is widely used to treat immunoreactive and inflammatory diseases.
However, the immunosuppressive activity of steroid treatment can also result in an increased susceptibility to a wide variety of infectious diseases. Previous in vitro studies have suggested that a significant increase in the number of inclusions was produced by a constant inoculum of chlamydia in epithelial cells incubated with steroid [18] [19] [20] .
Furthermore, experiments in a mouse model indicated that chlamydial reactivation and latent pulmonary infection were also stimulated by the presence of steroids [20, 21] .
Thus, these data strongly suggest that steroids increase the incidence of C. pneumoniae in the persistent phase in host cells, and that, in contrast, steroid antagonists may modify persistent infection by potentially inhibiting bacterial growth or directly killing bacteria.
The steroid receptor antagonist mifepristone (RU486), which is effective for termination of early pregnancy, has remarkable anti-steroid activity [22] . In the biopharmacological field, this drug is well characterized and used as a tool for analyzing steroid receptor signaling in cellular homeostasis [22] . We previously reported that RU486 directly binds to and kills C. pneumoniae within cells, indicating that the regulation of C. pneumoniae growth in cells by RU486 provides a new potential approach to drug therapy [23] . Furthermore, the fact implies that RU486 can kill C. pneumoniae regardless of the persistent infection with refractory disorder. To therefore investigate this approach, our current study aimed to examine whether treatment of host cells with steroid receptor antagonist RU486 inhibits C. pneumoniae growth during persistent infection induced by treatment with IFN . Although contrary to our 6 expectation RU486 treatment did not work on C. pneumoniae persistent infection at all, we show the data indicating that the expression of target molecule of RU486 on the bacteria obviously differs between normal developmental cycles and persistent stage, providing valuable insight into the complicated chlamydial biology.
Materials and methods

Cell line
Human epithelial cell line HEp-2 was kindly provided by R. Widen, Tampa General Hospital, Tampa, FL, USA. Cells were cultured in DMEM containing 10 % heatinactivated FCS and antibiotics (gentamicin sulfate, 10 g/ml; vancomycin, 10 g/ml; amphotericin B, 1 g/ml) (Sigma, St. Louis, MO) at 37 C in 5 % CO 2 . The absence of Mycoplasma in bacterial suspension and cell cultures were confirmed by touch-down PCR as reported previously [24] .
Bacteria
C. pneumoniae TW183 used in this study was kindly provided by G. Byrne, University of Wisconsin, Madison, WI. Bacteria were propagated in HEp-2 cell culture according to methods described previously [25] . Drugs RU486 (Sigma) was dissolved in ethanol to a stock concentration of 25 mM. The reagent was diluted to working concentrations using culture medium.
Infection
Cultured cells were infected with C. pneumoniae at a multiplicity of infection of 10 for 1 h at room temperature by centrifugation at 800 × g. After washing twice with medium, cells were resuspended in medium, and for immune staining, cells were placed on coverslips (diameter, 12 mm). Then infected cells were incubated for up to 72 h in the presence or absence of RU486 (10 or 25 M), with or without IFN (5-40 ng/ml) (Sigma). Infected cells treated with ethanol at concentrations equivalent to those in RU486 solutions were also prepared as a vehicle control (ethanol of 2500-fold diluted solution). After infection, the both drugs (RU486 and IFN) were simultaneously added in the cultures. Bacterial growth modification was assessed by IFU assay, fluorescence microscopic analysis and RT-PCR as shown below. Because it is well known that ofloxacin (OFLX) or clarithromycin (CAM) are ineffective against bacteria in the persistent phase [12] , these antibiotics were used as an indicator to confirm whether persistent infection occurred due to treatment with IFN.
Cell viability
The effect of RU486 on the viability of C. pneumoniae-infected cells with or without IFN was measured by counting viable cells. In brief, 2, 24, 48 and 72 h after treatment of C. pneumoniae-infected cells with RU486, cells were washed with phosphate-buffered saline (PBS; Sigma), detached with trypsin-EDTA (Sigma), and then suspended in medium. Cell viability was determined as a measure of trypan blue exclusion, and viable cells were counted using a hemocytometer. As a result, HEp-2 cells incubated for up to 72 h with working concentrations of RU486 and IFN did not show any significant cytotoxicity (data not shown).
IFU assay
C. pneumoniae infectivity was measured by counting chlamydial inclusions formed in HEp-2 cells that were visualized with FITC-conjugated monoclonal anti-Chlamydia antibody specific to Chlamydia LPS (Denka Seiken, Tokyo, Japan) [inclusion-forming unit (IFU) assay] [25, 26] . The detection limit for the IFU assay was 1 IFU per culture.
Fluorescence microscopic analysis
To determine inclusion formation, the infected cells fixed with ethanol were stained with FITC-conjugated monoclonal anti-Chlamydia antibody specific to Chlamydia LPS (Denka Seiken) and then assessed using fluorescence microscopy.
RT-PCR
Total RNA was extracted from cultures using a RNeasy Mini Kit (Qiagen, Valencia, CA) according to the manufacturer's protocol for bacterial cells. Extracted RNA was treated with DNase I (DNA-free; Ambion, Austin, TX) to eliminate contaminating 9 DNA. The resulting RNA preparations were confirmed to be DNA-free when a negative result was produced using PCR without the reverse transcription step. Reverse transcription of 2 g of total RNA by avian myeloblastosis virus reverse transcriptase was performed with random primers in a commercial reaction mixture (Reverse Transcription System; Promega, Madison, WI). Resulting cDNAs were then subjected to PCR with pairs of primers specific for C. pneumoniae 16S rRNA [20] and hsp60 [20] .
As a control, PCR using primers specific to human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was performed as described previously [27] . Thermal cycler parameters included a denaturation step at 95C for 10 min, followed by 25- 
Statistical analysis
Statistical analysis was performed with the unpaired Student's t test.
Results
Establishment of C. pneumoniae persistent form in IFN-treated HEp-2 cells
The persistent form of C. pneumoniae in human epithelial HEp-2 cells was induced by treatment with IFN according to the method described previously [28] .
Development to the persistent stage was confirmed using IFU assay, fluorescence microscopic analysis and RT-PCR. As shown in Fig 1B, a significant decease in the number of infectious progenies was observed between IFN treated and non-treated cells. A minimal decease in infectious progenies appeared to be IFN concentration dependent. In contrast, a decrease in inclusion formation using fluorescence microscopic analysis was minimal and no difference in bacterial gene expression was observed regardless of the presence or absence of IFN; the size of inclusions in cells were relatively smaller than those observed for untreated cells (Fig 1A and C) . Also, a concentration of IFN (20ng / ml) with an optimal inhibitory effect on an increase of the bacterial progenies was selected and used for below experiments.
Effect of RU486 on persistent C. pneumoniae infection in IFN-treated HEp-2 cells
Initially, we confirmed the effect of RU486 treatment on the infective progenies of C. pneumoniae in normal HEp-2 cells cultivated over different time periods. RU486 treatment of C. pneumoniae-infected cells cultured without the addition of IFN resulted in a significant decrease of C. pneumoniae growth at 72 h after infection depending on drug concentration (Fig. 2A) . These results were identical to our previously reported findings [23] and ensured that the experimental conditions used for the present study were optimal for obtaining reproducible results. In contrast, treatment with RU486 slightly decreased the number of infectious progenies for persistent infections induced using IFN (Fig. 2B) . Similar results were observed when cells were treated with antibiotics such as OFLX or CAM, indicating that the effect of RU486 on persistent C. pneumoniae infection was minimal. To confirm this hypothesis, the presence of cellular inclusion bodies of C. pneumoniae was determined using fluorescence microscopic analysis. Immunostaining revealed that treatment with RU486 clearly inhibited the formation of C. pneumoniae-induced inclusion bodies in normal culture of HEp-2 cells at 72 h after infection and did not inhibit formation in cells treated with IFN (Fig. 3A) .
As unexpected, RU486 treatment diminished the bacterial gene expressions (16SrRNA and hsp60) depending on the drug concentration regardless of the presence or absence of IFN (Fig. 3B) . This finding is of contradiction, however it is possible that these gene expressions were less affected by the treatment with IFN. Taken together, these findings suggest that the effect of RU486 treatment on persistent C. pneumoniae infection is minimal, implying that the bacterial target molecule of RU486 is more strongly expressed during the normal developmental cycle for this bacterial species.
Discussion
Persistent infection of C. pneumoniae in HEp-2 cells was induced by the treatment with IFN, since accumulating evidence from studies using in vitro persistent infection models suggested that IFN was the most effective reagent for inducing persistent C. pneumoniae infection with an incomplete developmental cycle [1, 26, 28] . As a result, treatment with IFN had an obvious effect on the growth of C. pneumoniae, resulting in a decrease in number of infectious progenies and a reduction of inclusion size. Gene expression of the 16S rRNA, which is critical for C. pneumoniae survival in cells, remained unchanged. Thus, persistent C. pneumoniae infection in HEp-2 cells was stably induced using IFN and supported the persistent infection models described previously [26, 28] .
Since the presence of bacterial transcripts serves as a marker for viable and bacterial metabolic activity, the modification of C. pneumoniae gene expression by RU486 in persistent infection could be interpreted as evidence of bacterial non-viability. Therefore, whether the drug could modify bacterial gene expression of 16S rRNA and hsp60, which are essential for all metabolically active stages of C. pneumoniae, including noninfectious RBs in infected cells [15, 20, 29] , was assessed by RT-PCR analysis, with determining inclusion formation and the number of infectious progenies. However, interestingly, our data indicated a possibility that these gene expression were unlikely to enough reflect bacterial viability in persistent stage induced by IFN, although further study for seeking more appropriate gene makers reflecting bacterial viability in the stage should be needed.
Previous works suggested that persistent chlamydial infection might be associated with incomplete chlamydial development with sporadic production of EBs refractory to treatment with antibiotics, although its reason remains unknown [26, 28] . Therefore, we assumed that a decrease of the sporadic EBs with a drug might be a significant indicator to evaluate the elimination of C. pneumoniae in persistent infection, and assessed changes of the numbers of infectious progenies (by IFU assay) in persistent infection.
As compared with the control treated with IFN, a slight difference was observed in the number of infectious progenies and the inclusion formation for persistent infection induced by the treatment with IFN and treated with RU486. Similar results were observed using common antibiotics such as CAM and indicated that RU486 treatment could not enough eliminate bacteria that had developed to a persistent stage infection.
While this result was contrary to our expectation, it is noteworthy that RU486 may not access bacteria that have developed to the persistent phase. As reported previously, 13 RU486 treatment eliminates bacteria from cells as a consequence of direct binding of the drug to the bacteria as they undergo maturation in inclusion bodies. Therefore, it is most likely that the target molecule of RU486 is expressed strongly in bacteria undergoing the normal developmental cycle and not enough in bacteria undergoing the abnormal cycle associated with persistent infection. This is the first report to show that expression of the bacterial target molecule against a possible therapeutic drug differs between bacterial stages undergoing different developmental cycles. Although the target molecule of RU486 remains undetermined, it is possible that the molecule is strongly expressed in bacteria in the normal developmental cycle. As there is no effect of the drug on EB before cells become infected [23] , some of the molecules expressed during the mid to late stages of the active developmental cycle are thought to be candidates for the target molecule of RU486. The expression level for this target molecule appears to be arrested in persistent infection, implying that the molecule is directly associated with bacterial maturation through acceleration of the developmental cycle. The alteration of chlamydial gene expression in the persistent infection was well documented [16, 17, 26, 29] . In particular, the persistent stage of the bacteria was characterized by the downregulation of a broad range of genes, associating with metabolism and cell division; in contrast the genes regulating DNA repair and replication were normally expressing even in the persistent stage [29] . Therefore, it is possible that these genes regarding metabolism and/or cell division are attractive candidates as target molecule of RU486, although further study should be needed. RU486 is a well-known antiprogestin with a high affinity for the progesterone receptor and causes competitive binding to intracellular progesterone receptor [22] . However, BLAST searching revealed an absence of DNA sequence homology to the progesterone receptor on the C. pneumoniae 14 whole genome, and no expression of progesterone receptor in HEp-2 cells with or without C. pneumoniae infection in the presence or absence of RU486 was observed [23] . This indicated that the bacterial receptor of RU486 might not be the progesterone receptor homolog.
In conclusion, the steroid receptor antagonist RU486 inhibited growth of C. 
